Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy

Trial Profile

An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Midostaurin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 08 Dec 2018 Planned End Date changed from 27 Aug 2021 to 30 Dec 2021.
    • 08 Dec 2018 Planned primary completion date changed from 27 Aug 2021 to 29 Dec 2021.
    • 13 Jul 2018 Planned End Date changed from 23 Oct 2019 to 27 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top